caa a22 4500 463208056 CHVBK 20180405153131.0 cr unu---uuuuu 170326e20070201xx s 000 0 eng 10.1007/s10863-006-9062-x doi (NATIONALLICENCE)springer-10.1007/s10863-006-9062-x Lactate and malignant tumors: A therapeutic target at the end stage of glycolysis [Elektronische Daten] [Saroj Mathupala, Chaim Colen, Prahlad Parajuli, Andrew Sloan] Metabolic aberrations in the form of altered flux through key metabolic pathways are primary hallmarks of many malignant tumors. Primarily the result of altered isozyme expression, these adaptations enhance the survival and proliferation of the tumor at the expense of surrounding normal tissue. Consequently, they also expose a unique set of targets for tumor destruction while sparing healthy tissues. Despite this fact, development of drugs to directly target such altered metabolic pathways of malignant tumors has been under-investigated until recently. One such target is the ultimate step of glycolysis, which, as expected, presents itself as a metabolic aberration in most malignant tumors. Termed "aerobic glycolysis” due to abnormal conversion of pyruvic acid to lactic acid even under normoxia, the altered metabolism requires these tumors to rapidly efflux lactic acid to the microenvironment in order to prevent poisoning themselves. Thus, exposed is a prime "choke-point” to target these highly malignant, frequently chemo- and radio- resistant tumors. This review will focus on current outcomes in targeting lactate efflux in such tumors using glioma as a model, an ongoing project in our laboratory for the past half-decade, as well as supporting evidence from recent studies by others on targeting this "tail-end” of glycolysis in other tumor models. Springer Science+Business Media, LLC, 2007 Lactate nationallicence MCT nationallicence Monocarboxylate transport nationallicence Glioma nationallicence Malignant tumors nationallicence MCT : monocarboxylate transporter nationallicence LDH : lactate dehydrogenase nationallicence siRNA : small intefering RNA nationallicence miRNA : microRNA nationallicence CD : cluster of differentiation nationallicence Mathupala Saroj Department of Neurological Surgery and Karmanos Cancer Institute, Wayne State University School of Medicine, 808 HWCRC, 4100 John R. Road, 48201, Detroit, MI, USA aut Colen Chaim Department of Neurological Surgery, Wayne State University School of Medicine, 48201, Detroit, MI, USA aut Parajuli Prahlad Department of Neurological Surgery, Wayne State University School of Medicine, 48201, Detroit, MI, USA aut Sloan Andrew Neuro-Oncology Program, H. Lee Moffitt Cancer Center, University of South Florida, 33612, Tampa, Fl, USA aut Journal of Bioenergetics and Biomembranes Kluwer Academic Publishers-Plenum Publishers; http://www.springer-ny.com 39/1(2007-02-01), 73-77 0145-479X 39:1<73 2007 39 10863 https://doi.org/10.1007/s10863-006-9062-x text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10863-006-9062-x text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Mathupala Saroj Department of Neurological Surgery and Karmanos Cancer Institute, Wayne State University School of Medicine, 808 HWCRC, 4100 John R. Road, 48201, Detroit, MI, USA aut NATIONALLICENCE 700 1- Colen Chaim Department of Neurological Surgery, Wayne State University School of Medicine, 48201, Detroit, MI, USA aut NATIONALLICENCE 700 1- Parajuli Prahlad Department of Neurological Surgery, Wayne State University School of Medicine, 48201, Detroit, MI, USA aut NATIONALLICENCE 700 1- Sloan Andrew Neuro-Oncology Program, H. Lee Moffitt Cancer Center, University of South Florida, 33612, Tampa, Fl, USA aut NATIONALLICENCE 773 0- Journal of Bioenergetics and Biomembranes Kluwer Academic Publishers-Plenum Publishers; http://www.springer-ny.com 39/1(2007-02-01), 73-77 0145-479X 39:1<73 2007 39 10863 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer